Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor.

The oncogene signal transducer and activator of transcription 3 (Stat3) is constitutively activated in a wide variety of human cancers, including squamous cell carcinoma of the head and neck. In squamous cell carcinoma of the head and neck, Stat3 activation is mediated by up-regulation of the autocrine ligand-receptor pair, tumor growth factor alpha and epidermal growth factor receptor (EGFR), resulting in cell growth and resistance to apoptosis. The initiating molecular event in Stat3 activation is recruitment to specific phosphotyrosine motifs within signaling complexes. Stat3 activation by the EGFR has been mapped to the COOH-terminal region of the EGFR between amino acid residues 1061 and 1123, which contains Y1068 and Y1086. However, it is not known if Stat3 binds directly to the EGFR or if either of these tyrosines is involved in this interaction. In this study, we demonstrated in stably transfected NIH-3T3 cells that activation of Stat3 by EGFR was eliminated by mutation of all five EGFR tyrosines to phenylalanine and that activation was restored with return of two of the mutated tyrosine sites, Y1068 and Y1086, to wild-type. Stat3 was detected in the activated EGFR complex, and its presence within the complex was dependent on Y1068 and/or Y1086. Phosphododecapeptides spanning Y1068 and Y1086 were able to pull down Stat3 with Y1068 being more effective than Y1086 in this regard. Real-time mirror resonance affinity analysis revealed Stat3 bound to phosphododecapeptide Y1068 with a K(D) of 135 +/- 20 nM and to phosphododecapeptide Y1086 with a K(D) of 243 +/- 36 nM (P = 0.044), consistent with the results of the pull-down assays. The lower K(D) of Y1068 was completely attributable to slower dissociation of Stat3 bound to Y1068 versus Y1086. Each phosphododecapeptide was capable of destabilizing Stat3 homodimers in vitro. When delivered into squamous carcinoma cells, phosphopeptides spanning Y1068 and Y1086 were able to inhibit EGFR-stimulated Stat3 DNA binding activity and cell proliferation.

[1]  M. Cascio,et al.  Identification of a novel Stat3 recruitment and activation motif within the granulocyte colony-stimulating factor receptor. , 1999, Blood.

[2]  J. Darnell,et al.  Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors , 1995, Science.

[3]  R. Schreiber,et al.  Stat recruitment by tyrosine-phosphorylated cytokine receptors: an ordered reversible affinity-driven process. , 1995, Immunity.

[4]  J. Schlessinger,et al.  Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor , 1994, Molecular and cellular biology.

[5]  Roy Garcia,et al.  STATs in oncogenesis , 2000, Oncogene.

[6]  J. Downward,et al.  Autophosphorylation sites on the epidermal growth factor receptor , 1984, Nature.

[7]  Y. Kido,et al.  Tyrosines 1148 and 1173 of activated human epidermal growth factor receptors are binding sites of Shc in intact cells. , 1994, The Journal of biological chemistry.

[8]  A. Ullrich,et al.  The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. , 2001, Endocrine-related cancer.

[9]  D. Tweardy,et al.  Granulocyte colony-stimulating factor rapidly activates a distinct STAT-like protein in normal myeloid cells. , 1995, Blood.

[10]  P. Coffer,et al.  EGF receptor deletions define a region specifically mediating STAT transcription factor activation. , 1995, Biochemical and biophysical research communications.

[11]  D. Levy,et al.  Ras-independent growth factor signaling by transcription factor tyrosine phosphorylation. , 1993, Science.

[12]  D. Nathans,et al.  In vitro activation of Stat3 by epidermal growth factor receptor kinase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  T. Beckers,et al.  Perinuclear localization of the protein-tyrosine phosphatase SHP-1 and inhibition of epidermal growth factor-stimulated STAT1/3 activation in A431 cells. , 2000, European journal of cell biology.

[14]  T. Carey,et al.  Clonogenic cell assay for anchorage‐dependent squamous carcinoma cell lines using limiting dilution , 1989, International journal of cancer.

[15]  J. Lammers,et al.  STAT3β, a Splice Variant of Transcription Factor STAT3, Is a Dominant Negative Regulator of Transcription* , 1996, The Journal of Biological Chemistry.

[16]  J. Grandis,et al.  Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. , 1998, The Journal of clinical investigation.

[17]  J. Darnell,et al.  Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. , 1994, Science.

[18]  M. David,et al.  Epidermal Growth Factor (EGF) Receptor Kinase-independent Signaling by EGF* , 2001, The Journal of Biological Chemistry.

[19]  T. Torgerson,et al.  Inhibition of Nuclear Translocation of Transcription Factor NF-κB by a Synthetic Peptide Containing a Cell Membrane-permeable Motif and Nuclear Localization Sequence (*) , 1995, The Journal of Biological Chemistry.

[20]  D. Levy,et al.  Roles of JAKs in activation of STATs and stimulation of c-fos gene expression by epidermal growth factor , 1996, Molecular and cellular biology.

[21]  J Godovac-Zimmermann,et al.  Phosphotyrosine 1173 Mediates Binding of the Protein-tyrosine Phosphatase SHP-1 to the Epidermal Growth Factor Receptor and Attenuation of Receptor Signaling* , 1998, The Journal of Biological Chemistry.

[22]  Y. Kido,et al.  Grb2/Ash binds directly to tyrosines 1068 and 1086 and indirectly to tyrosine 1148 of activated human epidermal growth factor receptors in intact cells. , 1994, The Journal of biological chemistry.

[23]  E. Petricoin,et al.  Requirement for MAP kinase (ERK2) activity in interferon alpha- and interferon beta-stimulated gene expression through STAT proteins. , 1995, Science.

[24]  J. Grandis,et al.  Downmodulation of TGF‐α protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells , 1998, Journal of cellular biochemistry.

[25]  J. Turkson,et al.  Phosphotyrosyl Peptides Block Stat3-mediated DNA Binding Activity, Gene Regulation, and Cell Transformation* , 2001, The Journal of Biological Chemistry.

[26]  P. Seeburg,et al.  Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells , 1984, Nature.

[27]  J. Baselga,et al.  PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  A. Ullrich,et al.  SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992 as the high‐affinity binding site for SH2 domains of phospholipase C gamma. , 1992, The EMBO journal.

[29]  T. Pawson,et al.  The tyrosine phosphorylated carboxyterminus of the EGF receptor is a binding site for GAP and PLC‐gamma. , 1990, The EMBO journal.

[30]  D. Tweardy,et al.  Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells , 1997, Oncogene.

[31]  G. Carpenter,et al.  The Role of Individual SH2 Domains in Mediating Association of Phospholipase C-γ1 with the Activated EGF Receptor* , 1999, The Journal of Biological Chemistry.

[32]  N. Stahl,et al.  STAT3 activation by cytokines utilizing gp130 and related transducers involves a secondary modification requiring an H7-sensitive kinase. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Ling Xia,et al.  Identification of Both Positive and Negative Domains within the Epidermal Growth Factor Receptor COOH-terminal Region for Signal Transducer and Activator of Transcription (STAT) Activation* , 2002, The Journal of Biological Chemistry.

[34]  R. Cook,et al.  Binding specificity of a class II-restricted hepatitis B epitope by DR molecules from responder and nonresponder vaccine recipients. , 1998, Human immunology.

[35]  Alan Wells,et al.  STAT Activation by Epidermal Growth Factor (EGF) and Amphiregulin , 1996, The Journal of Biological Chemistry.

[36]  Monilola A. Olayioye,et al.  ErbB Receptor-induced Activation of Stat Transcription Factors Is Mediated by Src Tyrosine Kinases* , 1999, The Journal of Biological Chemistry.

[37]  S. McKnight,et al.  Components of a Stat recognition code: evidence for two layers of molecular selectivity. , 1995, Immunity.

[38]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[39]  J. Darnell,et al.  Stat3 Activation Is Required for Cellular Transformation by v-src , 1998, Molecular and Cellular Biology.

[40]  J. Turkson,et al.  Stat3 Activation by Src Induces Specific Gene Regulation and Is Required for Cell Transformation , 1998, Molecular and Cellular Biology.